REMS
Contraindicated in:
CCr <40 mL/min or serum creatinine >2 times the upper limit of normal;
Severe hepatic impairment
;Use Cautiously in:
Renal impairment (↑ risk of worsening renal function)
;Mild or moderate hepatic impairment
;↑risk of renal/hepatic impairment in older adults; ↑ risk of GI hemorrhage in older adults with malignancy and/or low platelet counts
.Derm: rash, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
EENT: ↑intraocular pressure, cataracts, hearing loss, lens opacities, retinal disorders
GI: diarrhea, nausea , vomiting, ↑liver enzymes, abdominal pain, drug-induced hepatitis, GI BLEEDING/ULCERATION, GI PERFORATION, HEPATOTOXICITY
GU: ↑serum creatinine, RENAL FAILURE
Hemat: agranulocytosis, neutropenia, thrombocytopenia, worsening anemia
MS: arthralgia
Resp: cough
Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)
Drug-drug:
Chronic Iron Overload Due to Blood Transfusions
Hepatic Impairment
Renal Impairment
CCr 4060 mL/min: ↓initial dose by 50%
.Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes
Hepatic Impairment
Moderate hepatic impairment: ↓initial dose by 50%.
Renal Impairment
CCr 4060 mL/min: ↓initial dose by 50%.
Absorption: Well absorbed (70%) following oral administration; absorption is less in children.
Distribution: Unknown.
Protein Binding: 99%.
Half-Life: 816 hr.
NDC Code